Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
Protein-Drug Binding: Determination Methods01:22

Protein-Drug Binding: Determination Methods

Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.

Cancer immunology, immunotherapy : CII·2017
Same author

Feasibility of Singlet Analysis for Ligand Binding Assays: a Retrospective Examination of Data Generated Using the Gyrolab Platform.

The AAPS journal·2016
Same author

Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assays.

Bioanalysis·2015
Same author

Serum β-nerve growth factor concentrations in pregnant female, nonpregnant female, and male cynomolgus monkeys.

Neuroreport·2014
Same author

Discovery biotherapeutics bioanalysis: challenges and possible solutions.

Bioanalysis·2012
Same author

Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764).

Journal of medicinal chemistry·2011
Same journal

Branched-Chain Amino Acids (BCAAs): Metabolism and Their Roles In Inflammation Regulation and Disease.

Current drug metabolism·2026
Same journal

Corrigendum to: Nanocochleates in Clinical Trials: A Review of Current Status, Challenges, and Future Directions.

Current drug metabolism·2026
Same journal

Shenfu Decoction Extends Survival Time of Seawater-Induced Hypothermia in Rats: The Role of Metabolomics and Gut Microbiota.

Current drug metabolism·2026
Same journal

Nucleic Acid Nanomaterials Targeting Autophagy in Bone Regeneration.

Current drug metabolism·2026
Same journal

Nicotinamide N-Methyltransferase (NNMT): A Central Regulator in Hepatocellular Carcinoma Metabolism and Therapeutic Targeting - A Systematic Review.

Current drug metabolism·2026
Same journal

Chlorzoxazone-based One-Sample Method for Estimating In Vivo CYP2E1 Activity in Mice.

Current drug metabolism·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

Protein Digestion, Ultrafiltration, and Size Exclusion Chromatography to Optimize the Isolation of Exosomes from Human Blood Plasma and Serum
09:22

Protein Digestion, Ultrafiltration, and Size Exclusion Chromatography to Optimize the Isolation of Exosomes from Human Blood Plasma and Serum

Published on: April 13, 2018

Plasma/serum protein binding determinations.

Michael J Banker1, Tracey H Clark

  • 1Pfizer Inc, 8118W-209, Eastern Point Road, Groton CT 06340, USA. michael.j.banker@pfizer.com

Current Drug Metabolism
|November 11, 2008
PubMed
Summary
This summary is machine-generated.

Drug binding to serum proteins impacts drug transport, efficacy, and clearance. Understanding unbound drug fractions is crucial for accurate pharmacokinetic and pharmacodynamic modeling in drug discovery.

Related Experiment Videos

Last Updated: Jun 28, 2026

Protein Digestion, Ultrafiltration, and Size Exclusion Chromatography to Optimize the Isolation of Exosomes from Human Blood Plasma and Serum
09:22

Protein Digestion, Ultrafiltration, and Size Exclusion Chromatography to Optimize the Isolation of Exosomes from Human Blood Plasma and Serum

Published on: April 13, 2018

Area of Science:

  • Pharmacology
  • Drug Discovery
  • Biochemistry

Background:

  • Drug binding to serum proteins facilitates blood transport to target sites.
  • Only the unbound drug fraction is available for tissue diffusion, therapeutic interaction, and clearance.
  • Serum protein binding significantly influences pharmacokinetic (PK) parameters like clearance and volume of distribution.

Purpose of the Study:

  • To highlight the critical role of serum protein binding in drug discovery and development.
  • To emphasize the necessity of determining unbound drug fractions for PK/PD modeling.
  • To underscore the impact of protein binding on drug efficacy and disposition.

Main Methods:

  • Standard parameter evaluation in drug discovery.
  • In vivo modeling calculations for volume of distribution and organ clearance.
  • Analysis of pharmacokinetic and pharmacodynamic parameters.

Main Results:

  • Serum protein binding extent directly affects drug clearance rates and volume of distribution.
  • Unbound drug fraction is essential for therapeutic target interaction and xenobiotic clearance.
  • Accurate determination is vital for scaling PK/PD parameters from preclinical models to humans.

Conclusions:

  • Serum protein binding is an essential parameter in drug discovery and preclinical development.
  • Accurate assessment of unbound drug fraction is critical for effective pharmacokinetic and pharmacodynamic modeling.
  • Increased demand for these studies is driven by advancements in synthesis, in silico modeling, and early in vivo evaluations.